Recombinant Proteins
Product List
LMX1B Human
LIM Homeobox Transcription Factor 1, Beta Human Recombinant
LMX1B is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
STAP1 Human
Signal Transducing Adaptor Family Member 1 Human Recombinant
STAP1 is fused to a 24 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
STAR Human
Steroidogenic Acute Regulatory Protein Human Recombinant
STAR is fused to a 21 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
LRIG1 Mouse
Leucine Rich Repeats And Immunoglobulin Like Domains 1 Mouse Recombinant
LRIG1 Mouse produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 770 amino acids (35-796 a.a.) and having a molecular mass of 84.8kDa.
LRIG1 is expressed with an 8 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Sf9, Baculovirus cells.
STARD5 Human
StAR-Related Lipid Transfer Domain Containing 5 Human Recombinant
LRP2BP Human
LRP2 Binding Protein Human Recombinant
LRP2BP is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
STBD1 Human
Starch Binding Domain 1 Human Recombinant
STBD1 is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
LRP4 Human
LDL Receptor Related Protein 4 Human Recombinant
LRP4 Human Recombinant is a single, glycosylated polypeptide chain containing 1719 amino acids (21-1725a.a) and having a molecular mass of 191.6kDa (calculated). LRP4 is fused to a 14 a.a His tag (2 a.a on N-terminal and 12 a.a on C-terminal).
HEK293 Cells.
LCP2 Human
Lymphocyte Cytosolic Protein 2 Human Recombinant
LCP2 produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain (1-533 a.a.) and fused to a 6 aa His Tag at C-terminus containing a total of 542 amino acids and having a molecular mass of 61.2kDa.
LCP2 is purified by proprietary chromatographic techniques.
STEAP4 Human
STEAP Family Member 4 Human Recombinant
Introduction
The term “Other” can be defined in various contexts. In a general sense, it refers to something or someone that is different or distinct from the one already mentioned or known . In biological taxonomy, classification involves organizing living organisms into hierarchical categories based on their characteristics and evolutionary history .
Biological properties of “Other” can be understood through key characteristics shared by living organisms, such as order, sensitivity or response to stimuli, reproduction, growth and development, regulation, homeostasis, and energy processing . These properties are expressed in various patterns and distributed across different tissues, contributing to the organism’s overall function and survival.
The primary biological functions of “Other” include catalyzing chemical reactions, synthesizing and repairing DNA, transporting materials across cells, receiving and sending chemical signals, responding to stimuli, and providing structural support . These functions play crucial roles in immune responses and pathogen recognition, ensuring the organism’s defense mechanisms are active and effective .
Modes of action describe the functional or anatomical changes resulting from exposure to a substance. This includes the interaction with other molecules and cells, binding partners, and downstream signaling cascades . For example, a mode of action could involve binding to DNA, leading to transcriptional regulation .
Regulatory mechanisms control the expression and activity of “Other” through transcriptional regulation and post-translational modifications . These mechanisms ensure that the biological processes are carried out efficiently and accurately, adapting to the organism’s needs and environmental changes.
In biomedical research, “Other” has various applications, including diagnostic tools and therapeutic strategies . For instance, understanding the biological properties and functions of different molecules can lead to the development of new treatments and diagnostic methods, improving healthcare outcomes.
